Ridgeback Biotherapeutics initiates Phase II Covid-19 trials
EIDD-2801 will be given to Covid-19 patients aged 18 years and above in two Phase II trials. Credit: mattthewafflecat from Pixabay.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more